The Buy-side Backlog

Automation

The tremendous growth in OTC derivatives is driving increased spending in automation of reference data, with rapidly scaling businesses struggling to deal with data management. The expansion presents challenges to both buy-side and sell-side institutions, but the barriers to be overcome tend to be different.

Having invested heavily in automation of OTC derivatives in recent years, larger sell-side institutions focused on creating strong infrastructures are in a different phase of the data

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

Waters Wrap: The tough climb for startups

Anthony speaks with two seasoned technologists to better understand why startups have such a tough time getting banks and asset managers to sign on the dotted line.

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here